Warfarin pharmacogenetics: To genotype or not to genotype, that is the question

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 1, 2014, Pages 22-24

  Cavallari, L H ^a   Nutescu, E A ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C18; CYTOCHROME P450 2C9; WARFARIN;

AFRICAN AMERICAN; ALGORITHM; ALLELE; BLEEDING; COST EFFECTIVENESS ANALYSIS; CYP2C18 GENE; CYP2C9 GENE; DRUG DOSE REGIMEN; DRUG METABOLISM; GENE; GENETIC ASSOCIATION; GENOTYPE; HIP ARTHROPLASTY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KNEE ARTHROPLASTY; ORTHOPEDIC SURGERY; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS; VKORC1 GENE;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS AS TOPIC; CONTINENTAL POPULATION GROUPS; GENOTYPE; HUMANS; PHARMACOGENETICS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84902664193     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.78     Document Type: Review

References (10)

1. Holbrook, A. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2 suppl.), e152S-184S (2012)
2. Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011)
3. Pirmohamed, M. et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369, 2294-2303 (2013)
4. Kimmel, S.E. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369, 2283-2293 (2013)
5. Klein, T.E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009)
6. Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009)
7. Perera, M.A. et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382, 790-796 (2013)
8. Cavallari, L.H. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87, 459-464 (2010)
9. Do, E.J. et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12, 417-424 (2012)
10. Nutescu, E.A. et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy 33, 1156-1164 (2013)